1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
PeptiDream Inc.

PeptiDream Inc.

PPTDF
PeptiDream Inc.US flagOther OTC
6.65
USD
+0.65
- -
854.47MMarket Cap
PeptiDream Inc.
PPTDF
(Other OTC)

Recent

price

6.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.14
7.62
7.64
22.62
38.94
42.84
53.26
58.41
- -
92.92
73.09
206.83
221.37
360.14
143.21
427.58
Revenue per Share
0.12
1.54
1.39
9.18
14.23
16.54
19.35
22.42
- -
35.4
19.96
58.19
23.41
115.85
-28.99
167.35
Basic EPS, GAAP
-2.42
1.37
-0.01
1.35
-3.92
-3.53
-12.01
34.69
- -
9.12
42.2
-31.26
85.21
166.86
-116.23
-6.03
Free Cash Flow per Basic Share
0.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.55
33.37
29.21
37.94
59.48
76.49
92.18
112.56
- -
142.21
157.71
214.17
244.88
411.63
383.09
433.8
Book Value per Share
3.82
63.97
54.72
63.16
91.2
105.51
120.93
140.27
- -
168.21
196.07
165.13
229.51
356.84
318.11
372.33
Tangible Book Value per Share
86
89
107
109
111
114
121
124
- -
126
129
130
130
130
129
130
Basic Weighted Avg Shares
269
678
819
2,474
4,328
4,896
6,427
7,217
- -
11,677
9,422
26,852
28,712
46,677
18,521
55,420
Sales/Revenue/Turnover
-6.76
23.71
24.59
56.22
58.88
50.87
45.29
49.6
- -
59.87
43.16
33.44
23.59
45.23
-27.07
58.48
Operating Margin (%)
42
52
74
103
143
195
513
521
- -
571
633
1,973
2,433
2,248
2,127
2,367
Depreciation Expense
10
137
149
1,004
1,581
1,891
2,335
2,770
- -
4,448
2,573
7,554
3,036
15,015
-3,749
21,690
Net Income, GAAP
- -
21.21
33.1
32.76
33.16
27.95
25.91
27.23
- -
26.11
32.35
- -
30.27
28.12
- -
28.19
Effective Tax Rate (%)
3.71
20.23
18.14
40.58
36.54
38.62
36.34
38.39
- -
38.09
27.31
28.13
10.57
32.17
-20.24
39.14
Profit Margin (%)
222
5,531
5,699
5,538
6,901
7,174
6,345
7,931
7,361
10,935
12,460
14,042
18,608
38,803
15,501
43,532
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
18,358
19,634
17,042
- -
18,339
LT Debt
327
5,696
5,863
6,912
10,243
12,181
14,709
17,449
16,978
21,217
25,350
32,041
40,350
56,762
51,528
58,771
Total Equity
- -
4.13
2.31
14.06
18.52
15.33
15.53
15.52
- -
25.88
11.39
- -
7.94
20.51
- -
33.25
Return on Invested Capital (%)
- -
8.6
4.87
27.59
29.39
24.63
23.51
22.13
- -
28.43
13.47
- -
8.96
24.4
- -
37.7
Return on Capital (%)
- -
8.6
4.87
27.59
29.39
24.63
23.51
22.13
- -
28.43
13.47
31.39
10.19
35.28
-7.29
52.08
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
2,586
2,588
2,590
LT Borrowings
19,634
18,987
18,339
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
130
130
130
Market Capitalization
158,169
- -
296,270

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
27,225
35,372
61,782
Cash, Cash Equivalents & STI
19,514
27,341
25,484
Accounts Receivable, Net
4,971
4,729
32,766
Inventories
2,404
2,738
2,790
Total Current Liabilities
8,617
10,100
18,250
Payables & Accruals
- -
- -
- -
ST Debt
2,586
2,588
2,590
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.38%
20.65%
-9.22%
Free Cash Flow
- -
-49.25%
-169.51%
Net Income, GAAP
- -
72.25%
-124.97%
Sales/Revenue/Turnover
- -
34.97%
-60.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,225
31,908
- -
- -
46,677
2025
- -
- -
- -
- -
18,521
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.5
144.8
- -
- -
115.85
2025
- -
- -
- -
- -
-28.99
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Bio-Gene Technology Limited (BGT.AX)
C4 Therapeutics, Inc. (CCCC)
Nanobiotix S.A. (NNBXF)
Orphazyme A/S (ORPHY)
OptiBiotix Health Plc (OPBXF)
Aerovate Therapeutics, Inc. (AVTE)
Business
PeptiDream Inc. engages in the biopharmaceutical business focused on the discovery and development of non-standard peptide therapeutics using its proprietary Peptide Discovery Platform System (PDPS), which generates trillions of diverse macrocyclic and constrained peptide libraries for identifying potent hit candidates that develop into peptide-based therapeutics, small molecule drugs, and peptide-drug conjugates (PDCs). The company offers PDPS-based services including collaborative drug discovery research and development with global pharmaceutical partners, technology licensing, and internal pipeline expansion through strategic alliances targeting oncology, radiopharmaceuticals, and other unmet medical needs; its core products encompass macrocyclic peptides, peptide-radioisotope conjugates for diagnostics and therapeutics, and optimized candidates for PDC payloads such as radionuclides. PeptiDream operates primarily in the Drug Discovery and Development Business segment, serving major pharmaceutical companies worldwide with a focus on healthcare markets in Japan, the United States, and Europe. Founded in 2006 by Kiichi Kubota and Hiroaki Suga and headquartered in Kawasaki, Japan, the company maintains operations through subsidiaries like PDRpharma for peptide-radiopharmaceutical development in Japan. Recent major developments include the April 2024 expansion of its PDC partnership with Novartis, providing $180 million upfront and potential milestones up to $2.7 billion plus royalties for PDPS-identified macrocyclic peptides conjugated to radionuclides, alongside ongoing radiopharmaceutical pipeline progress and a FY25 revenue forecast adjustment to ¥18 billion reflecting deal timing shifts into FY26.

Company News

APIChatGPT

  • businesswire.com

    PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer

  • businesswire.com

    PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

  • globenewswire.com

    Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

  • businesswire.com

    PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner

  • seekingalpha.com

    PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript

  • globenewswire.com

    Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan

  • businesswire.com

    PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis